```json
[
    {
        "primary_name": "Inflammatory Bowel Disease",
        "candidates": ["Inflammatory Bowel Disease (IBD)", "IBD"],
        "entity_name": "Inflammatory Bowel Disease (IBD)",
        "type": "Disease",
        "description": "A group of inflammatory conditions of the gastrointestinal tract, including Crohn's disease and ulcerative colitis.",
        "is_ambiguous": false
    },
    {
        "primary_name": "Crohn's disease",
        "candidates": ["Crohn's disease", "Crohn disease"],
        "entity_name": "Crohn's disease",
        "type": "Disease",
        "description": "A type of inflammatory bowel disease that can affect any part of the gastrointestinal tract.",
        "is_ambiguous": false
    },
    {
        "primary_name": "Ulcerative colitis",
        "candidates": ["Ulcerative colitis", "Colitis ulcerosa"],
        "entity_name": "Ulcerative colitis",
        "type": "Disease",
        "description": "A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract.",
        "is_ambiguous": false
    },
    {
        "primary_name": "Dual-targeted therapy for Inflammatory Bowel Disease",
        "candidates": ["Dual-targeted therapy (DTT) for Inflammatory Bowel Disease", "Dual-targeted therapy for IBD"],
        "entity_name": "Dual-targeted therapy (DTT) for Inflammatory Bowel Disease",
        "type": "Drug",
        "description": "A therapeutic approach targeting multiple pathways to enhance treatment efficacy for inflammatory bowel disease.",
        "is_ambiguous": false
    },
    {
        "primary_name": "Therapeutic Agents Targeting Cellular Signaling Pathways for Inflammatory Bowel Disease",
        "candidates": ["Therapeutic Agents Targeting Cellular Signaling Pathways for IBD", "Cellular Signaling Pathway Agents for IBD"],
        "entity_name": "Therapeutic Agents Targeting Cellular Signaling Pathways for IBD",
        "type": "Drug",
        "description": "A category of drugs that target signaling pathways involved in cellular processes related to inflammatory bowel disease.",
        "is_ambiguous": false
    },
    {
        "primary_name": "Therapeutic Agents Targeting Leukocyte Trafficking in Inflammatory Bowel Disease",
        "candidates": ["Therapeutic Agents Targeting Leukocyte Trafficking in IBD", "Leukocyte Trafficking Agents for IBD"],
        "entity_name": "Therapeutic Agents Targeting Leukocyte Trafficking in IBD",
        "type": "Drug",
        "description": "Drugs that affect the movement of leukocytes, which are involved in the inflammatory response in diseases like IBD.",
        "is_ambiguous": false
    },
    {
        "primary_name": "JAK-dependent therapeutic agents for Inflammatory Bowel Disease",
        "candidates": ["JAK-dependent therapeutic agents for IBD", "JAK-dependent agents for IBD"],
        "entity_name": "JAK-dependent therapeutic agents for Inflammatory Bowel Disease",
        "type": "Drug",
        "description": "Drugs that act through the Janus kinase signaling pathway, involved in immune response regulation.",
        "is_ambiguous": false
    },
    {
        "primary_name": "JAK-independent therapeutic agents for Inflammatory Bowel Disease",
        "candidates": ["JAK-independent therapeutic agents for IBD", "JAK-independent agents for IBD"],
        "entity_name": "JAK-independent therapeutic agents for Inflammatory Bowel Disease",
        "type": "Drug",
        "description": "Drugs that do not rely on the Janus kinase pathway for their therapeutic action.",
        "is_ambiguous": false
    }
]
```